Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B83f6fd3781f4d72b238d1e4490a206f6> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B83f6fd3781f4d72b238d1e4490a206f6 NCIT_P378 "NCI" @default.
- B83f6fd3781f4d72b238d1e4490a206f6 type Axiom @default.
- B83f6fd3781f4d72b238d1e4490a206f6 annotatedProperty IAO_0000115 @default.
- B83f6fd3781f4d72b238d1e4490a206f6 annotatedSource NCIT_C155654 @default.
- B83f6fd3781f4d72b238d1e4490a206f6 annotatedTarget "A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, garivulimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T-cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation." @default.